Rock Springs Capital BCAX Position
Active7-Fund ConvergenceRock Springs Capital increased their position in Bicara Therapeutics Inc. (BCAX) in Q4 2025, holding $7.2M worth of shares across 429,095 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
BCAX is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Ficerafusp alfa in 745 days (Apr 30, 2028), making the timing of Rock Springs's position particularly relevant.
Short interest stands at 20.8% of float with 14.7 days to cover, indicating significant bearish positioning against Rock Springs's long thesis.
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Full company profile →Short Interest
20.8%
14.7 days to cover
Rock Springs Capital BCAX Position History
Frequently Asked Questions
Does Rock Springs Capital own BCAX?
Yes. As of Q4 2025, Rock Springs Capital holds 429,095 shares of Bicara Therapeutics Inc. (BCAX) valued at $7.2M. This data comes from their SEC 13F filing.
How many hedge funds own BCAX?
7 specialist biotech hedge funds currently hold BCAX, including RA Capital Management, Deerfield Management, Deep Track Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy BCAX?
Rock Springs Capital's position in BCAX was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's BCAX position increasing or decreasing?
Rock Springs Capital increased their BCAX position in the most recent quarter, adding 58,429 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BCAXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →